Merck in Talks to Acquire Cubist for ~$100/Share
Merck & Co Inc. (NYSE: MRK), is reportedly in talks to acquire Lexington, MA-based Cubist Pharmaceuticals Inc. (NASDAQ: CBST) for around $7.5 billion, or approximately $100 per share according to the NY Times DealBook. A deal could be announced as early as next week, according to persons familiar with the matter.
Cubist shares closed Friday at $74.36, down $0.16.
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.